Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$6.53 USD
+0.49 (8.11%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.52 -0.01 (-0.15%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNGX 6.53 +0.49(8.11%)
Will TNGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNGX
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
Other News for TNGX
Tango Therapeutics management to meet with Cantor Fitzgerald
Tango Therapeutics management to meet with Cantor Fitzgerald
Tango Therapeutics management to meet with Cantor Fitzgerald
TNGX: Upcoming Meetings in San Francisco and Denver
Tango Therapeutics management to meet with Cantor Fitzgerald